Navigation Links
Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments
Date:11/9/2009

SAN DIEGO, Nov. 9, 2009 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today reported financial results for the third quarter ended September 30, 2009.

Arena reported a lower net loss allocable to common stockholders in the third quarter of 2009 of $34.8 million, or $0.38 per share, compared to a net loss allocable to common stockholders in the third quarter of 2008 of $56.2 million, or $0.76 per share, and a net loss allocable to common stockholders in the first nine months of 2009 of $123.4 million, or $1.51 per share, compared to a net loss allocable to common stockholders in the first nine months of 2008 of $177.0 million, or $2.40 per share.

"The successful completion of the lorcaserin pivotal program in the third quarter was a critical milestone for Arena," stated Jack Lief, Arena's President and Chief Executive Officer. "The positive results were received with support and enthusiasm at The Obesity Society's annual meeting last month. Participating physicians shared with us three clear themes: the pressing need for new weight management treatments, the paramount importance of safety in treating overweight and obese patients, and that weight reduction should translate into improvements in cardiometabolic health. If approved, the unique combination of efficacy, safety and tolerability positions lorcaserin as first-line therapy."

As expected, research and development expenses declined significantly to $22.1 million in the third quarter of 2009 from $47.5 million in the third quarter of 2008. Research and development expenses declined to $89.0 million in the first nine months of 2009 from $151.0 million in the first nine months of 2008. This decrease is primarily due to the completion of the BLOOM (Behavioral modification and Lorcaserin for Overweight and Obesity Management) and BLOSSOM (Behav
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Arena Pharmaceuticals to Present at Four Upcoming Investor Conferences
2. Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia
3. Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes
4. Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Clinical Trial
5. Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
6. Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd.
7. Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial Results of APD125 for the Treatment of Insomnia at 22nd Annual Meeting of the Associated Professional Sleep Societies
8. Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis
9. Critical Pharmaceuticals Enter Sustained Release hGH Arena
10. Arena Pharmaceuticals Announces Preliminary Results of Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
11. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Type 2 Diabetes Drug Candidate in Partnership with Ortho-McNeil-Janssen Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2015)... -- Research and Markets ( ... "Veterinary Pharmaceutical Submissions in the EU (London, ... their offering. This practical two-day course ... parts of the application for marketing authorisation for ... authorisation is sought in the European Union, including ...
(Date:9/4/2015)... 4, 2015 Hutchison China ... Hutchison MediPharma Limited ("HMP"), its drug R&D subsidiary, ... proof-of-concept ("POC") trial of fruquintinib in patients with ... China .  The top-line results ... the primary efficacy endpoint of progression free survival ...
(Date:9/3/2015)... Sept. 3, 2015 With a population of ... country and therefore also its single largest potential market ... China has led all major world economies in the ... expenditures, and government health expenditures. As an in vitro ... markets of the United States, western European countries, and ...
Breaking Medicine Technology:Veterinary Pharmaceutical Submissions in the EU: Two day Course - London, UK - December 7-8, 2015 2Second Proof-of-concept Trial of Fruquintinib Achieves its Primary Endpoint 2Second Proof-of-concept Trial of Fruquintinib Achieves its Primary Endpoint 3IVD in China 2IVD in China 3IVD in China 4IVD in China 5IVD in China 6IVD in China 7IVD in China 8IVD in China 9IVD in China 10IVD in China 11IVD in China 12IVD in China 13
... (OTC Bulletin Board: ACUR) (the "Company") today announced ... "Agreement"), with an,investor group comprised of Vivo Ventures ... L.P., GCE Holdings LLC and certain individual investors,(the ... Units ("Units") at a price of $1.08 per ...
... 20 Ranbaxy Pharmaceuticals Inc.,(RPI), a wholly owned ... RLL has received approval from the U.S. Food ... and,Acetaminophen Tablets USP, 7.5 mg/750 mg, 10 mg/500 ... The Office of Generic Drugs, U.S. Food and ...
Cached Medicine Technology:Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate 2Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate 3Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP 2
(Date:9/5/2015)... PA (PRWEB) , ... September 05, 2015 , ... "I ... period," said one of two inventors from Phoenix, Ariz. "I came up with this ... but to help with rehabilitation too." , They developed the KNEE BUDDY to comfortably ...
(Date:9/5/2015)... , ... September 05, 2015 , ... If you are ... of accidental needle sticks, there is a greater need than ever before for an ... NON SLIP GRIP SYRINGE to protect medical staff members and patients against accidental needle ...
(Date:9/5/2015)... ... September 05, 2015 , ... As school supply lists continue to increase and budgets ... demands for their students. William Mattar Law Offices has found a way to help ... teachers as well as principals and superintendents as in past years. Because of that, ...
(Date:9/4/2015)... ... September 04, 2015 , ... According to an article ... being cared for in nursing homes and assisted living facilities are receiving insufficient care ... story in which her father was at one point close to death, not because ...
(Date:9/4/2015)... (PRWEB) , ... September 04, 2015 , ... According to ... the Journal of the American Dental Association presented data showing that it is safe ... a group of pregnant women that had undergone local anesthesia with a group that ...
Breaking Medicine News(10 mins):Health News:InventHelp Inventor Develops Therapeutic Knee Support (PHO-2061) 2Health News:Safety Feature for Needle Injections Invented by InventHelp Client (OCM-914) 2Health News:‘Pencils 4 Schools’ Campaign 2015 Exceeds Expectations from Previous Year 2Health News:Op-Ed about Insufficient Care for Elderly Patients Highlights the Advantages of Quality, At-Home Care, says Dr. Michael Farzam 2Health News:Op-Ed about Insufficient Care for Elderly Patients Highlights the Advantages of Quality, At-Home Care, says Dr. Michael Farzam 3Health News:Recent Study on Dental Care During Pregnancy Demonstrates How Preventative Dental Care Really is for Everyone, Says Medical Center Dental Care 2
... ... and Caicos clinical facilities allowing the islands to provide access to medical specialists, improve ... ... supplier of telemedicine technology , devices, and application software for both dynamic encounters ...
... ... successful 57-year old Reno, Nevada, dentist – and mystic! -- has ... that belongs in every spiritual seeker’s library. In ... The Transformation of Spirituality” (Gene Pascucci Publishing, 2010), Pascucci tells his ...
... A study forthcoming in the Journal of Political Economy ... higher death rates in U.K. hospitals. The U.K.,s National ... nation,s health care, sets wages for nurses and other health ... flat throughout the country, despite the fact that wages for ...
... to prevent mistakes, review finds , WEDNESDAY, May 12 (HealthDay ... that caffeine consumption can help night-shift workers avoid making mistakes. ... are thought to be engaged in shift work or permanent ... from shift-work disorder, in which they only sleep for short ...
... that can cause trouble, experts say , WEDNESDAY, May 12 ... to implant and maintain could make life better for people ... report. , A defibrillator delivers an electric shock to restart ... are implanted in Americans each year. Current models require careful ...
... could be a significant predictor of responses to vaccines, ... of Public Health. They examined published data from numerous ... is a fundamental, but often overlooked predictor of vaccine ... infectious disease. The review is featured in the May ...
Cached Medicine News:Health News:AMD Global Telemedicine Inc. Chosen by InterHealth Canada as the Telemedicine Solutions Provider for Turks and Caicos Hospital Project 2Health News:AMD Global Telemedicine Inc. Chosen by InterHealth Canada as the Telemedicine Solutions Provider for Turks and Caicos Hospital Project 3Health News:"What If We're Him?" -- New Book Poses Provocative Perspective on Jesus, God 2Health News:"What If We're Him?" -- New Book Poses Provocative Perspective on Jesus, God 3Health News:Can wage regulation be deadly? 2Health News:New Implanted Defibrillator May Be Simpler, Safer 2Health News:New Implanted Defibrillator May Be Simpler, Safer 3Health News:Response to vaccines could depend on your sex 2
... are designed specifically for medical environments. Resulting ... with professional monitors, the LMD-151MD offer uncompromising ... requirements and are ideal for use in ... Slim and light, they can be used ...
A comprehensive bioresorbable product line comprised of implants and accessories that serve craniomaxillofacial, neurosurgical, and iliac crest reconstruction....
... Major advancement in craniomaxillofacial fixation. Completely resorbable, ... titanium. Today, it is the most thoroughly ... available as LactoSorb SE, with system enhancements ... LactoSorb SEs streamlined delivery system means that ...
1.7/2.2 mm Delta System resorbable implant technology merges science and simplicity for a superior craniomaxillofacial surgery product. The system consists of resorbable bone plates and screws fabric...
Medicine Products: